Whitehawk Therapeutics (NASDAQ:WHWK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Whitehawk Therapeutics (NASDAQ:WHWK) from a sell rating to a hold rating in a research report released on Saturday morning.

A number of other research analysts also recently issued reports on WHWK. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Monday, December 29th. Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday, February 5th. They set an “outperform” rating and a $6.00 target price on the stock. Finally, JonesTrading initiated coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.50.

Whitehawk Therapeutics Stock Performance

Shares of WHWK stock opened at $3.65 on Friday. Whitehawk Therapeutics has a fifty-two week low of $1.39 and a fifty-two week high of $4.48. The firm has a market cap of $172.28 million, a P/E ratio of 7.77 and a beta of 0.50. The business’s 50 day moving average price is $3.16 and its 200-day moving average price is $2.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of WHWK. Quadrature Capital Ltd purchased a new position in Whitehawk Therapeutics during the 4th quarter valued at about $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new stake in Whitehawk Therapeutics in the third quarter worth about $51,000. Dimensional Fund Advisors LP bought a new position in shares of Whitehawk Therapeutics during the third quarter valued at approximately $84,000. Squarepoint Ops LLC bought a new position in shares of Whitehawk Therapeutics during the third quarter valued at approximately $159,000. Finally, Marshall Wace LLP purchased a new position in shares of Whitehawk Therapeutics during the fourth quarter valued at approximately $164,000. 52.08% of the stock is currently owned by institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.